# NEOpredict (NCT04205552)

> Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04205552
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University Hospital, Essen
- Conditions: NSCLC Stage II; NSCLC, Stage IIIA; NSCLC, Stage I
- Interventions: Nivolumab 10 MG/ML Intravenous Solution; Relatlimab 10 MG/ML Intravenous Solution
- Enrollment: 90
- Primary outcome: Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neopredict-nct04205552